Testosterone in 2026: The Research Just Got More Complicated, and That's Good News for Men
Something unusual happened in men's health this year. The evidence on testosterone got better and more complicated at the same time — and the combination undercuts both camps in the argument. If you've been following the "low T" conversation, here's where it actually stands. First, the reassurance The TRAVERSE trial randomized more than 5,200 men aged 45–80 with documented hypogonadism and elevated cardiovascular risk to testosterone gel or placebo, followed for a median of roughly 22 months. The primary outcome — cardiovascular death, heart attack or stroke — came in at 7.0% in the testosterone group, meeting non-inferiority. That settled a question that had hung over the field for a decade. In 2025, the FDA removed the boxed cardiovascular warning from testosterone labels, while adding a blood-pressure warning. For men with genuine, properly diagnosed hypogonadism, that's meaningful. Treatment that works, with the main cardiovascular fear addresse...